Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: September 21, 2023
Reporting Period: Event-based report regarding regulatory compliance status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial metric disclosed is the stock price deficiency:
- Stock Price Deficiency: The 30-day trading average price of common stock fell below $0.20 per share.
Material Changes
On September 21, 2023, the Company received a deficiency letter from the NYSE American LLC indicating non-compliance with Section 1003(f)(v) of the NYSE American Company Guide due to the low share price. This event triggers specific compliance procedures but has no immediate effect on the listing or trading of the stock.
Guidance, Outlook, and Risks
Compliance Timeline and Actions
The Company must demonstrate sustained price improvement or effect a reverse stock split no later than March 21, 2024, to regain compliance. Failure to cure the deficiency by this date may result in the initiation of delisting proceedings.
Management Commentary
Management intends to monitor the stock price closely and consider available options to regain compliance. The Company is actively engaged in discussions with the Exchange and developing plans to meet the standards within the cure period. The receipt of the letter does not affect business operations or SEC reporting requirements.
Risks and Contingencies
If delisted and unable to list on another national exchange, the stock may trade over-the-counter, potentially resulting in:
- Limited availability of market quotations and reduced liquidity.
- Classification as a "penny stock," subjecting brokers to stricter rules and potentially reducing trading activity.
- Reduced news and analyst coverage.
- Decreased ability to issue additional securities or obtain financing.
- Loss of "covered security" status, subjecting the Company to state-level securities regulations.
Investor Verification Checklist
- Verify the current 30-day trading average price of MTNB to assess progress toward the $0.20 threshold.
- Monitor for announcements regarding a potential reverse stock split before the March 21, 2024 deadline.
- Review subsequent filings for updates on discussions with the NYSE American regarding compliance plans.
- Assess the impact of potential delisting on liquidity and the Company's ability to raise capital.